Effectiveness of sacubitril–valsartan in cancer patients with heart failure

[Aims] Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy‐related cardiac dysfunction (CTRCD). Our aim was to analyse the potential benefit...

ver descrição completa

Detalhes bibliográficos
Autores: Martín-García, Ana, López-Fernández, Teresa, Mitroi, Cristina, Chaparro‐Muñoz, Marinela, Moliner, Pedro, Martín‐García, Agustín C., Martinez‐Monzonis, Amparo, Castro Dorado, Antonio, López-Sendón, José Luis, Sánchez, Pedro L.
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/235817
Acesso em linha:http://hdl.handle.net/10261/235817
Access Level:acceso abierto
Palavra-chave:Cancer
Cardio-oncology
Cardiotoxicity
Heart failure
Sacubitril–valsartan
Descrição
Resumo:[Aims] Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy‐related cardiac dysfunction (CTRCD). Our aim was to analyse the potential benefit of sacubitril/valsartan in patients with CTRCD.

Registos relacionados